A review article examined up to date data of PBT for pancreatic cancer. For both resectable and unresectable pancreatic cancer, the clinical outcome data is limited but very encouraging and supports the need for additional trials to fully explore the benefits of PBT.

Existing data indicate that PBT combined with chemotherapy in the preoperative, adjuvant, and definitive settings is extremely well-tolerated and allows for the possibility of dose intensification. Several ongoing trials are investigating hypofractionated dose-escalated proton radiotherapy in combination with chemotherapy for unresectable/marginally resectable disease.